Published by Frank Prenesti on 15th December 2022
(Sharecast News) - The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.
URL: http://www.digitallook.com/dl/news/story/33180576/...